Andres Gutiérrez
Technik-/Wissenschafts-/F&E-Leiter bei ADVAXIS, INC.
Vermögen: 26 $ am 30.04.2024
Aktive Positionen von Andres Gutiérrez
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ADVAXIS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.01.2023 | - |
Karriereverlauf von Andres Gutiérrez
Ehemalige bekannte Positionen von Andres Gutiérrez
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AYALA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2018 | 25.03.2024 |
ONCOLYTICS BIOTECH INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.11.2016 | 23.04.2018 |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2015 | 01.09.2016 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.10.2012 | 01.11.2015 |
Instituto Nacional de Salud Pública de México | Corporate Officer/Principal | - | - |
Instituto Nacional de Ciencias Medicas y Nutricion
Instituto Nacional de Ciencias Medicas y Nutricion Hospital/Nursing ManagementHealth Services Instituto Nacional de Ciencias Medicas y Nutricion operates hospitals. The private company is based in Mexico City, Mexico. | Corporate Officer/Principal | - | - |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Technik-/Wissenschafts-/F&E-Leiter | - | - |
BIOMARIN PHARMACEUTICAL INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Andres Gutiérrez
Universidad Nacional Autónoma de México | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Mexiko | 4 |
Bermuda | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 9 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 10 |
Consumer Services | 2 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
SONOMA PHARMACEUTICALS, INC. | Health Technology |
ONCOLYTICS BIOTECH INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
AYALA PHARMACEUTICALS, INC. | Commercial Services |
Private Unternehmen | 7 |
---|---|
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Instituto Nacional de Ciencias Medicas y Nutricion
Instituto Nacional de Ciencias Medicas y Nutricion Hospital/Nursing ManagementHealth Services Instituto Nacional de Ciencias Medicas y Nutricion operates hospitals. The private company is based in Mexico City, Mexico. | Health Services |
Old Ayala, Inc.
Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
Instituto Nacional de Salud Pública de México |
- Börse
- Insiders
- Andres Gutiérrez
- Erfahrung